199 related articles for article (PubMed ID: 23515368)
1. Tumor-targeted liposomal drug delivery mediated by a diseleno bond-stabilized cyclic peptide.
Li C; Wang Y; Zhang X; Deng L; Zhang Y; Chen Z
Int J Nanomedicine; 2013; 8():1051-62. PubMed ID: 23515368
[TBL] [Abstract][Full Text] [Related]
2. A stabilized peptide ligand for multifunctional glioma targeted drug delivery.
Ying M; Shen Q; Zhan C; Wei X; Gao J; Xie C; Yao B; Lu W
J Control Release; 2016 Dec; 243():86-98. PubMed ID: 27693752
[TBL] [Abstract][Full Text] [Related]
3. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region.
Amin M; Mansourian M; Koning GA; Badiee A; Jaafari MR; Ten Hagen TLM
J Control Release; 2015 Dec; 220(Pt A):308-315. PubMed ID: 26526970
[TBL] [Abstract][Full Text] [Related]
4. LyP-1-conjugated PEGylated liposomes: a carrier system for targeted therapy of lymphatic metastatic tumor.
Yan Z; Wang F; Wen Z; Zhan C; Feng L; Liu Y; Wei X; Xie C; Lu W
J Control Release; 2012 Jan; 157(1):118-25. PubMed ID: 21827801
[TBL] [Abstract][Full Text] [Related]
5. Structure Reconstruction of LyP-1:
Zhang X; Wang F; Shen Q; Xie C; Liu Y; Pan J; Lu W
Mol Pharm; 2018 Feb; 15(2):430-436. PubMed ID: 29215294
[TBL] [Abstract][Full Text] [Related]
6. LyP-1-conjugated doxorubicin-loaded liposomes suppress lymphatic metastasis by inhibiting lymph node metastases and destroying tumor lymphatics.
Yan Z; Zhan C; Wen Z; Feng L; Wang F; Liu Y; Yang X; Dong Q; Liu M; Lu W
Nanotechnology; 2011 Oct; 22(41):415103. PubMed ID: 21914940
[TBL] [Abstract][Full Text] [Related]
7. LyP-1 modification to enhance delivery of artemisinin or fluorescent probe loaded polymeric micelles to highly metastatic tumor and its lymphatics.
Wang Z; Yu Y; Ma J; Zhang H; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
Mol Pharm; 2012 Sep; 9(9):2646-57. PubMed ID: 22853186
[TBL] [Abstract][Full Text] [Related]
8. Lipopepsomes: A novel and robust family of nano-vesicles capable of highly efficient encapsulation and tumor-targeted delivery of doxorubicin hydrochloride in vivo.
Qiu M; Sun H; Meng F; Cheng R; Zhang J; Deng C; Zhong Z
J Control Release; 2018 Feb; 272():107-113. PubMed ID: 29355618
[TBL] [Abstract][Full Text] [Related]
9. Liposome-based glioma targeted drug delivery enabled by stable peptide ligands.
Wei X; Gao J; Zhan C; Xie C; Chai Z; Ran D; Ying M; Zheng P; Lu W
J Control Release; 2015 Nov; 218():13-21. PubMed ID: 26428462
[TBL] [Abstract][Full Text] [Related]
10. Design and In Vitro Evaluation of Bispecific Complexes and Drug Conjugates of Anticancer Peptide, LyP-1 in Human Breast Cancer.
Timur SS; Bhattarai P; Gürsoy RN; Vural İ; Khaw BA
Pharm Res; 2017 Feb; 34(2):352-364. PubMed ID: 27896591
[TBL] [Abstract][Full Text] [Related]
11. Design of Y-shaped targeting material for liposome-based multifunctional glioblastoma-targeted drug delivery.
Belhadj Z; Ying M; Cao X; Hu X; Zhan C; Wei X; Gao J; Wang X; Yan Z; Lu W
J Control Release; 2017 Jun; 255():132-141. PubMed ID: 28390902
[TBL] [Abstract][Full Text] [Related]
12. Deepened cellular/subcellular interface penetration and enhanced antitumor efficacy of cyclic peptidic ligand-decorated accelerating active targeted nanomedicines.
Shi NQ; Li Y; Zhang Y; Li ZQ; Qi XR
Int J Nanomedicine; 2018; 13():5537-5559. PubMed ID: 30271146
[TBL] [Abstract][Full Text] [Related]
13. A liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or density.
Gray BP; McGuire MJ; Brown KC
PLoS One; 2013; 8(8):e72938. PubMed ID: 24009717
[TBL] [Abstract][Full Text] [Related]
14. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A
Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474
[TBL] [Abstract][Full Text] [Related]
15. Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect.
Xie Q; Deng W; Yuan X; Wang H; Ma Z; Wu B; Zhang X
Eur J Pharm Biopharm; 2018 Jan; 122():87-95. PubMed ID: 29032193
[TBL] [Abstract][Full Text] [Related]
16. Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas.
Amin M; Badiee A; Jaafari MR
Int J Pharm; 2013 Dec; 458(2):324-33. PubMed ID: 24148663
[TBL] [Abstract][Full Text] [Related]
17. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
18. PEGylated liposomal doxorubicin targeted to α5β1-expressing MDA-MB-231 breast cancer cells.
Shroff K; Kokkoli E
Langmuir; 2012 Mar; 28(10):4729-36. PubMed ID: 22268611
[TBL] [Abstract][Full Text] [Related]
19. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
[TBL] [Abstract][Full Text] [Related]
20. LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors.
Luo G; Yu X; Jin C; Yang F; Fu D; Long J; Xu J; Zhan C; Lu W
Int J Pharm; 2010 Jan; 385(1-2):150-6. PubMed ID: 19825404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]